PHN-010 / Pheon Therap - LARVOL DELTA

A Study of PHN-010 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=273 | Active, not recruiting | Sponsor: Pheon Therapeutics | Recruiting ➔ Active, not recruiting

Enrollment closed • Cervical Cancer • Colon Cancer • Colorectal Cancer • Endometrial Cancer • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

A Study of PHN-010 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=273 | Recruiting | Sponsor: Pheon Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Cervical Cancer • Colon Cancer • Colorectal Cancer • Endometrial Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

A Study of PHN-010 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=273 | Not yet recruiting | Sponsor: Pheon Therapeutics

Metastases • New P1 trial • Cervical Cancer • Colon Cancer • Colorectal Cancer • Endometrial Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

Pheon Therapeutics announces $120m Series B financing to fund development of its differentiated ADC pipeline (PRNewswire) - "Pheon Therapeutics...today announces the completion of a $120m Series B financing to fund the development of its pipeline of differentiated ADCs....The new financing will be used to further advance Pheon's differentiated ADC pipeline through clinical proof of concept. The first three assets are aimed at an undisclosed novel target which is highly overexpressed in a wide range of solid tumors. The first program has demonstrated an unprecedented preclinical therapeutic index while utilizing a DAR8 Topoisomerase-1 inhibitor linker-payload, whereas the next two ADCs utilize other linker-payload technologies to mine the broad potential of this target. The company expects to start its first Phase 1 clinical trial in 2024 and rapidly advance towards dose expansion cohorts. The capital will also enable the expansion of Pheon's suite of in-house technology platforms to generate optimized ADC constructs."

Financing • New P1 trial • Oncology • Solid Tumor

With $68M Series A, Pheon Breaks into Competitive ADC Space (BioSpace) - "U.K.-based biotech Pheon Therapeutics launched Wednesday with $68 million in Series A financing and a vision of ushering in the next generation of antibody-drug conjugates....The company plans on using its Series A proceeds to see PHN-010 through a clinical proof-of-concept study....With extensive preclinical data, including expression profiling in diseased and healthy tissues, and in vivo efficacy, PHN-010 is expected to be ready for an investigational new drug application within 18 months."

Commercial • IND • Oncology